OBJECTIVE: Oxidative stress induces vasoconstriction, hypercoagulation and pathologic vascular remodeling. We hypothesized that maternally-administered melatonin may reduce oxidative stress, hypercoagulability and structural injury in placenta, and prevent fetal sequelae in a mouse model of intrauterine inflammation(IUI)-induced oxidative stress. STUDY DESIGN: CD1 pregnant dams were randomized to intrauterine injections of either lipopolysaccharide (LPS; a model of IUI) or phosphate-buffered saline (PBS) at E17 as follows: (1) control (C); (2) Melatonin (M); (3) LPS (L); (4) LPS with Melatonin group (LM). Doppler ultrasonography was utilized to obtain fetal and maternal hemodynamic measurements in utero. Proinflammatory mediators (NFkB, TNFa, and IL1b), oxidative stress markers (4-HNE) and antioxidant mediators (Nrf2, HO1) were analyzed in the placenta by real-time RT-qPCR and western blots. Confirmatory histochemistry (PTAH, H&E, Nissl staining) and immunohistochemical analyses (Vimentin & CD31, a vascular endothelial cell marker; and Iba1, a marker of microglial activation) were performed. RESULTS: The systolic/diastolic (S/D) ratio, resistance index (RI) and pulsatility index (PI) in uterine artery (UtA) and umbilical artery (UA) were significantly increased in L compared to C, M, or ML groups. The rate of early diastolic notch in the UtA and the rate of absent end-diastolic flow (AEDF) in UA were significantly higher in L than C, M, or ML. Tei indices were significantly increased in L compared to C, M, or ML. The rate of abnormal Tei indices (>0.44) was significantly higher in L compared to C, M, or ML. The expression of SIRT1, Nrf2 and HO1 in the placenta were significantly decreased in L comparing to C or ML. The expression of NFkB, TNFa, and IL1b were significantly increased in L comparing to C, and ML. 4-HNE was increased in L comparing to C, M and ML. The area of vimentin in the placenta was decreased in L than C or M. PTAH staining in the placenta showed increased deposit of fibrin in L comparing to C, M, or ML. Iba1 expression was increased in fetal brains in L compared to C, M, and ML. CONCLUSION: Maternal pretreatment with melatonin appears to modulate maternal placental malperfusion, fetal cardiovascular compromise and fetal neuroinflammation induced by intrauterine oxidative stress. Current results suggest that melatonin could serve as a new preventive and/or therapeutic agent to prevent fetal injury from IUI-induced oxidative stress.
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Poster Session III 
OBJECTIVE:
To evaluate the effectiveness of cervical pessary in singleton pregnancies for the prevention of preterm birth (PTB) through an ongoing 'dynamic' systematic review and meta-analysis. STUDY DESIGN: A systematic review was completed in Medline, EMBASE, Web of Science, Cochrane CENTRAL, and ClinicalTrials. gov. All randomised controlled trials (RCTs) that studied the use of the cervical pessary compared to a control group in singleton pregnancies were included. Delivery, maternal and neonatal outcomes were evaluated comprising the core outcome set for PTB. The summary measures were reported as relative risk (RR) with 95% of confidence interval (CI) using a random effects model. A Higgins I 2 of >80% was considered to be high heterogeneity and therefore the trial estimates were not pooled. The quality of evidence for prespecified outcomes was assessed using the GRADE methodology. We plan to perform an ongoing 'dynamic' meta-analysis by repeating the systematic review and analysis every 6 months.
RESULTS:
Six qualifying trials were identified, all trials studied the use of pessary with CL <25mm (n¼1,992 pessary vs 999 controls). Four trials administrated vaginal progesterone to the pessary and control group. There were no significant differences seen in the rates of spontaneous PTB (sPTB) or any PTB prior to 28, 34, or 37 weeks (Table 1) . There was high heterogeneity noted for sPTB <34 weeks (I 2 ¼84%, n¼1,830) (Figure 1 ). Three trials found no significant reduction in sPTB rate <34 weeks, while two trials demonstrated a significant reduction (6.3% vs 26.8%; 7.3% vs 15.3%, respectively). Women with pessaries were more likely to report increased vaginal discharge at follow up visits (66% vs 28%, I
2 ¼82%, n¼1,830) and pelvic pain (RR 3.35, 95% CI 2.00-5.60, n¼1,288). Only 5.4% requested removal of the pessary. There were no significant differences in delivery or neonatal outcomes. CONCLUSION: Singleton gestations with short CL randomized to cervical pessary did not have a significant difference in rates of preterm birth compared to controls. However, these results demonstrate the large heterogeneity in both the statistical analysis as well as in the results of individual trials. We plan to continue to investigate using a 'dynamic' systematic review and meta-analysis to include forthcoming trials. OBJECTIVE: Quantitative fetal fibronectin (qfFN) in cervicovaginal fluid at 16-22 weeks has been used to stratify risk for spontaneous preterm birth (sPTB) in high-risk asymptomatic women. We sought to determine the clinical utility of qfFN in high-risk patients who have undergone an intervention to prevent sPTB, either cervical cerclage, vaginal progesterone (vag-P), or 17-P. STUDY DESIGN: This is a secondary analysis of the EQUATE trial, a prospective, multicenter, observational study designed to evaluate the utility of qfFN for predicting risk of sPTB in a high-risk, asymptomatic cohort. Subgroup analyses were performed based on the presence or absence of risk factors (prior sPTB, short cervix, twins) and interventions to prevent sPTB (cerclage, vag-P, or 17-P).
Outcomes included the proportion of treated and untreated women experiencing sPTB <32, <35, and <37 weeks at qfFN concentrations <10, 10-199, and 200 ng/mL.
